经皮椎体成形术联合碘-125粒子植入治疗伴硬膜囊压迫的脊柱转移瘤:回顾性对比研究
该回顾性对比研究分析2013年6月至2021年6月55例(75节椎体)伴硬膜囊压迫的脊柱转移瘤患者,比较经皮椎体成形术(PVP)联合碘-125粒子植入与单纯PVP的疗效与安全性。联合组25例(40节椎体),对照组30例(35节椎体)。两组技术成功率均为100%,联合组长期疼痛缓解、功能状态及局部肿瘤控制均优于单纯PVP,且无严重并发症。
要点
- PVP联合碘-125粒子植入治疗伴硬膜囊压迫的脊柱转移瘤技术成功率达100%。
- 联合组12个月VAS评分更低、KPS更高,长期疼痛缓解和功能改善优于单纯PVP。
- 联合组局部肿瘤控制率80%高于对照组55.5%,两组均无严重并发症。
核心结论
- PVP联合碘-125粒子植入是治疗伴硬膜囊压迫脊柱转移瘤可行、安全且有效的替代方案,较单纯PVP提供更优的持续疼痛缓解和局部肿瘤控制。
研究设计与样本
- 回顾性对比研究,分析2013年6月至2021年6月55例(75节椎体)伴硬膜囊压迫的脊柱转移瘤患者。
- 联合组25例(40节椎体)接受PVP联合碘-125粒子植入,对照组30例(35节椎体)接受单纯PVP。
- 采用VAS评估疼痛、KPS评估功能状态,并通过随访影像评估局部肿瘤控制。
主要发现
- 两组技术成功率均为100%。
- 12个月时联合组平均VAS评分为2.08 ± 1.97,低于对照组的4.04 ± 0.93。
- 12个月时联合组平均KPS为90.80 ± 1.17,高于对照组的64.00 ± 3.04。
- 对照组VAS和KPS分别在3个月和6个月后无显著改善。
- 联合组局部肿瘤控制率为80%,高于对照组的55.5%。
关键数值与推荐
- 联合组12个月平均VAS评分2.08 ± 1.97,对照组4.04 ± 0.93。
- 联合组12个月平均KPS 90.80 ± 1.17,对照组64.00 ± 3.04。
- 联合组局部肿瘤控制率80%,对照组55.5%。
- 两组均无脊髓损伤或肺栓塞等严重并发症。
临床怎么用
- 对于伴硬膜囊压迫的脊柱转移瘤患者,可考虑PVP联合碘-125粒子植入以获取更优的长期疼痛缓解和局部肿瘤控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of percutaneous vertebroplasty (PVP) combined with iodine-125 seed implantation versus PVP alone for spinal metastases with dural sac compression. METHODS: This retrospective comparative study analyzed 55 patients (75 vertebrae) treated between June 2013 and June 2021. Patients were categorized into 2 groups: the Combined Group (n = 25, 40 vertebrae) received PVP plus iodine-125 seed implantation, and the Control Group (n = 30, 35 vertebrae) received PVP alone. Clinical outcomes were assessed using the Visual Analog Scale (VAS) for pain, Karnofsky Performance Score (KPS) for functional status, and follow-up imaging for local tumor control. RESULTS: Technical success was 100% in both groups. While both techniques provided initial pain relief, the Combined Group demonstrated significantly superior long-term outcomes. At 12 months, the Combined Group had lower mean VAS scores (2.08 ± 1.97 vs. 4.04 ± 0.93) and higher mean KPS (90.80 ± 1.17 vs. 64.00 ± 3.04) compared to the Control Group. Intragroup analysis revealed that the Control Group showed no significant improvement in VAS or KPS beyond 3 and 6 months, respectively. The local tumor control rate was significantly higher in the Combined Group (80%) than in the Control Group (55.5%). No serious complications, such as spinal cord injury or pulmonary embolism, occurred in either cohort. CONCLUSIONS: PVP combined with interstitial iodine-125 seed implantation is a feasible, safe, and effective alternative to PVP alone. This combined approach offers superior sustained pain relief and local tumor control for patients with spinal metastases involving dural sac compression.
引用
- Xiao QP, Li SY. Percutaneous Vertebroplasty Combined with Iodine-125 Seed Implantation for Spinal Metastases with Dural Sac Compression: A Retrospective Comparative Study. World Neurosurg. 2025. PMID: 41482267. doi:10.1016/j.wneu.2025.124782
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。